116 related articles for article (PubMed ID: 19051810)
21. The combination of p53 and age predict cancer specific death in advanced stage (FIGO Ic-IV) of endometrial carcinoma of endometrioid type. An immunohistochemical examination of growth fraction: Ki-67, MIB-1 and PC10; suppressor oncogene protein: p53; oncogene protein: p185 and age, hormone treatment, stage, and histologic grade.
Nielsen AL; Nyholm HC
Eur J Obstet Gynecol Reprod Biol; 1996 Dec; 70(1):79-85. PubMed ID: 9031925
[TBL] [Abstract][Full Text] [Related]
22. ErbB family immunohistochemical expression in colorectal cancer patients with higher risk of recurrence after radical surgery.
Baiocchi G; Lopes A; Coudry RA; Rossi BM; Soares FA; Aguiar S; Guimarães GC; Ferreira FO; Nakagawa WT
Int J Colorectal Dis; 2009 Sep; 24(9):1059-68. PubMed ID: 19390858
[TBL] [Abstract][Full Text] [Related]
23. [Immunohistochemical markers expression in hysteroscopy and hysterectomy specimens from endometrial cancer patients: comparison].
Pilka R; Marková I; Dusková M; Zapletalová J; Tozzi M; Kudela M
Ceska Gynekol; 2010 May; 75(3):165-70. PubMed ID: 20731294
[TBL] [Abstract][Full Text] [Related]
24. Prognostic value of immunohistochemically detected HER-2/neu oncoprotein in endometrial cancer.
Kohlberger P; Loesch A; Koelbl H; Breitenecker G; Kainz C; Gitsch G
Cancer Lett; 1996 Jan; 98(2):151-5. PubMed ID: 8556702
[TBL] [Abstract][Full Text] [Related]
25. Simultaneous quantitative detection of relevant biomarkers in breast cancer by quantitative real-time PCR.
Labuhn M; Vuaroqueaux V; Fina F; Schaller A; Nanni-Metellus I; Kung W; Eppenberger-Castori S; Martin PM; Eppenberger U
Int J Biol Markers; 2006; 21(1):30-9. PubMed ID: 16711511
[TBL] [Abstract][Full Text] [Related]
26. Tumor expression of human growth hormone and human prolactin predict a worse survival outcome in patients with mammary or endometrial carcinoma.
Wu ZS; Yang K; Wan Y; Qian PX; Perry JK; Chiesa J; Mertani HC; Zhu T; Lobie PE
J Clin Endocrinol Metab; 2011 Oct; 96(10):E1619-29. PubMed ID: 21849525
[TBL] [Abstract][Full Text] [Related]
27. Prognostic impact of p53, c-erbB-2 and epidermal growth factor receptor on head and neck carcinoma.
Parise Junior O; Carvalho LV; Miguel RE; Kowalski LP
Sao Paulo Med J; 2004 Nov; 122(6):264-8. PubMed ID: 15692721
[TBL] [Abstract][Full Text] [Related]
28. p53, c-erbB-2 and the epidermal growth factor receptor in the benign and malignant prostate.
Mellon K; Thompson S; Charlton RG; Marsh C; Robinson M; Lane DP; Harris AL; Horne CH; Neal DE
J Urol; 1992 Feb; 147(2):496-9. PubMed ID: 1370701
[TBL] [Abstract][Full Text] [Related]
29. p53 protein and c-erbB-2 protein (p185) expression in endometrial adenocarcinoma of endometrioid type. An immunohistochemical examination on paraffin sections.
Nielsen AL; Nyholm HC
Am J Clin Pathol; 1994 Jul; 102(1):76-9. PubMed ID: 7913577
[TBL] [Abstract][Full Text] [Related]
30. Molecular profile of advanced-stage transitional cell carcinoma of the ovary.
Gershenson DM; Baker VV; Price JE; Hung MC; El-Naggar AK; Tortolero-Luna G; Silva EG
Am J Obstet Gynecol; 1997 Jul; 177(1):120-5. PubMed ID: 9240594
[TBL] [Abstract][Full Text] [Related]
31. p53 protein expression in human breast carcinoma: relationship to expression of epidermal growth factor receptor, c-erbB-2 protein overexpression, and oestrogen receptor.
Poller DN; Hutchings CE; Galea M; Bell JA; Nicholson RA; Elston CW; Blamey RW; Ellis IO
Br J Cancer; 1992 Sep; 66(3):583-8. PubMed ID: 1355662
[TBL] [Abstract][Full Text] [Related]
32. c-erbB-3 and c-erbB-2 protein expression in node-negative breast carcinoma--an immunocytochemical study.
Gasparini G; Gullick WJ; Maluta S; Dalla Palma P; Caffo O; Leonardi E; Boracchi P; Pozza F; Lemoine NR; Bevilacqua P
Eur J Cancer; 1994; 30A(1):16-22. PubMed ID: 7908213
[TBL] [Abstract][Full Text] [Related]
33. [Prognostic significance of clinic pathological and selected immunohistochemical factors in endometrial cancer].
Marková I; Pilka R; Dusková M; Zapletalová J; Kudela M
Ceska Gynekol; 2010 May; 75(3):193-9. PubMed ID: 20731299
[TBL] [Abstract][Full Text] [Related]
34. Prognostic significance of ER, PR, Ki67, c-erbB-2, and p53 in endometrial carcinoma.
Suthipintawong C; Wejaranayang C; Vipupinyo C
J Med Assoc Thai; 2008 Dec; 91(12):1779-84. PubMed ID: 19133508
[TBL] [Abstract][Full Text] [Related]
35. Epidermal growth factor receptor and c-erbB-2 oncoproteins in tissue and tumor effusion cells of histopathologically different ovarian neoplasms.
Harlozińska A; Bar JK; Sobańska E; Goluda M
Tumour Biol; 1998; 19(5):364-73. PubMed ID: 9701727
[TBL] [Abstract][Full Text] [Related]
36. Expression of the ErbB family of receptors in ovarian cancer.
Scoccia B; Lee YM; Niederberger C; Ilekis JV
J Soc Gynecol Investig; 1998; 5(3):161-5. PubMed ID: 9614647
[TBL] [Abstract][Full Text] [Related]
37. [Prognostic importance of selected molecular genetic immunohistochemical markers and DNA ploidy in endometrial cancer].
Kudela M; Pilka R; Lubuský M; Hejtmánek P; Dzubák P; Brychtová S
Ceska Gynekol; 2011 Jun; 76(3):194-9. PubMed ID: 21838149
[TBL] [Abstract][Full Text] [Related]
38. Overexpression of Wnt7a is associated with tumor progression and unfavorable prognosis in endometrial cancer.
Liu Y; Meng F; Xu Y; Yang S; Xiao M; Chen X; Lou G
Int J Gynecol Cancer; 2013 Feb; 23(2):304-11. PubMed ID: 23321718
[TBL] [Abstract][Full Text] [Related]
39. ErbB-3 predicts survival in ovarian cancer.
Tanner B; Hasenclever D; Stern K; Schormann W; Bezler M; Hermes M; Brulport M; Bauer A; Schiffer IB; Gebhard S; Schmidt M; Steiner E; Sehouli J; Edelmann J; Läuter J; Lessig R; Krishnamurthi K; Ullrich A; Hengstler JG
J Clin Oncol; 2006 Sep; 24(26):4317-23. PubMed ID: 16896008
[TBL] [Abstract][Full Text] [Related]
40. Molecular and cytokinetic pretreatment risk assessment in endometrial carcinoma.
Silverman MB; Roche PC; Kho RM; Keeney GL; Li H; Podratz KC
Gynecol Oncol; 2000 Apr; 77(1):1-7. PubMed ID: 10739683
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
